- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
56 result(s) found for: Testicular Cancer.
Displaying page 1 of 3.
EudraCT Number: 2010-021898-36 | Sponsor Protocol Number: INT 38/10 | Start Date*: 2010-10-20 | ||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||||||||||||||||||
Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment. | ||||||||||||||||||
Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004075-23 | Sponsor Protocol Number: SWENOTECA-ABC-1 | Start Date*: 2015-02-26 | |||||||||||
Sponsor Name:St Olavs University Hospital | |||||||||||||
Full Title: A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer | |||||||||||||
Medical condition: Stage I, Seminomatous, Testicular cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004450-28 | Sponsor Protocol Number: T109/2012 | Start Date*: 2013-02-18 | ||||||||||||||||
Sponsor Name:University of Turku [...] | ||||||||||||||||||
Full Title: Effect of chemotherapy on endothelial function in patients with testicular cancer | ||||||||||||||||||
Medical condition: Testicular cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004632-38 | Sponsor Protocol Number: GCTSK005 | Start Date*: 2017-11-09 | |||||||||||||||||||||
Sponsor Name:Národný onkologický ústav | |||||||||||||||||||||||
Full Title: Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer. | |||||||||||||||||||||||
Medical condition: Extracranial primary germ cell cancer, seminoma, or nonseminoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: SK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004667-61 | Sponsor Protocol Number: SUITE - CUOG-TE 05 | Start Date*: 2007-02-22 | |||||||||||
Sponsor Name:Universitätsklinikum Hamburg-Eppendorf | |||||||||||||
Full Title: Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study | |||||||||||||
Medical condition: germ cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004508-36 | Sponsor Protocol Number: FM-12-GCT01 | Start Date*: 2013-05-04 | |||||||||||
Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori | |||||||||||||
Full Title: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial | |||||||||||||
Medical condition: Patients with histologically-confirmed germ-cell cancer with exclusive or prevalent CD30-positive embryonal carcinoma component | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000731-28 | Sponsor Protocol Number: EORTC 30983 | Start Date*: 2006-03-23 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer | |||||||||||||
Medical condition: Patients with Intermediate Prognosis Germ cell Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004418-32 | Sponsor Protocol Number: TestisCAB | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:Oslo University Hospital - Cancer Department | |||||||||||||
Full Title: Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer. | |||||||||||||
Medical condition: Cisplatin-resistant germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) DK (Completed) SE (Ongoing) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
Medical condition: Testicular cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000894-19 | Sponsor Protocol Number: CA209-647 | Start Date*: 2016-09-28 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL) | ||||||||||||||||||
Medical condition: Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014383-18 | Sponsor Protocol Number: CRAD001CDE21T | Start Date*: 2010-08-12 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer | |||||||||||||
Medical condition: Germ cell tumor, metastatic, relapsed or refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005481-18 | Sponsor Protocol Number: BNT142-01 | Start Date*: 2022-04-28 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech SE | ||||||||||||||||||||||||||||||||||||||
Full Title: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced sol... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Claudin 6 (CLDN6)-positive advanced solid tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006295-29 | Sponsor Protocol Number: ICR-CTSU/2008/10019 | Start Date*: 2009-08-20 | |||||||||||
Sponsor Name:The Institute of Cancer Research [...] | |||||||||||||
Full Title: A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT) | |||||||||||||
Medical condition: Patients with newly diagnosed NSGCTT or mixed GCT (MGCT) with vascular invasion and stage 1 disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001452-30 | Sponsor Protocol Number: 010815testis | Start Date*: 2015-12-07 | |||||||||||
Sponsor Name:Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: A Randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig Cell Insufficiency (Einstein-intervention) | |||||||||||||
Medical condition: Leydig Cell dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003930-17 | Sponsor Protocol Number: 1407-GUCG | Start Date*: 2015-10-05 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLO... | |||||||||||||
Medical condition: progressive or recurrent germ cell tumor (measurable or non-measurable) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) SI (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004323-20 | Sponsor Protocol Number: BNT211-01 | Start Date*: 2020-06-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech Cell & Gene Therapies GmbH | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000514-11 | Sponsor Protocol Number: SAKK01/18 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:Swiss Group for Clinical Cancer Research (SAKK) | |||||||||||||
Full Title: Reduced intensity radio-chemotherapy for stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts | |||||||||||||
Medical condition: stage IIA/B seminoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001502-10 | Sponsor Protocol Number: GCTSK002 | Start Date*: 2011-09-28 |
Sponsor Name:National Cancer Institute | ||
Full Title: Phase II study of Everolimus in refractory testicular germ cell cancer. | ||
Medical condition: refractory metastatic germ cell tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000677-31 | Sponsor Protocol Number: STH15216 | Start Date*: 2011-09-16 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Testosterone Replacement in Young Male cancer Survivors | |||||||||||||
Medical condition: Borderline low levels of testosterone in male cancer survivors who have previously had leukaemia, lymphoma or testicular cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000558-68 | Sponsor Protocol Number: GCTSK006 | Start Date*: 2019-05-03 | |||||||||||
Sponsor Name:Národný onkologický ústav | |||||||||||||
Full Title: Phase II study of disulfiram and cisplatin in refractory testicular germ cell cancer. | |||||||||||||
Medical condition: platina refractory testicular germ cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
